Mode
Text Size
Log in / Sign up

Systematic review suggests resveratrol may improve glycemic control and protect pancreatic beta-cell function in diabetes.

Systematic review suggests resveratrol may improve glycemic control and protect pancreatic beta-cell…
Photo by Sandra Seitamaa / Unsplash
Key Takeaway
Consider resveratrol as a potential adjunct for glycemic control and pancreatic protection, though direct evidence in pancreatogenic diabetes is scarce.

This systematic review evaluates the potential metabolic and pancreatic protective effects of resveratrol in patients with type 2 diabetes mellitus and pancreatogenic diabetes. The scope encompasses experimental and clinical studies examining resveratrol's impact on glycemic control, inflammatory responses, oxidative stress, and pancreatic beta-cell function.

The authors synthesize findings indicating that resveratrol may improve glycemic control, attenuate inflammatory responses, reduce oxidative stress, and protect pancreatic beta-cell function. These conclusions are drawn from a body of evidence that includes both experimental models and clinical observations.

A key limitation noted is that direct studies investigating the role of resveratrol specifically in pancreatogenic diabetes remain scarce. The review highlights that future research specifically targeting pancreatic diseases associated with diabetes is needed to clarify the therapeutic potential of resveratrol in disorders affecting the exocrine–endocrine pancreatic axis. Consequently, the practice relevance is currently limited by the scarcity of direct clinical data in this specific population.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Pancreatic dysfunction plays an important role in the development and progression of diabetes mellitus. Resveratrol, a naturally occurring polyphenolic compound, has attracted considerable interest due to its antioxidant, anti-inflammatory, and metabolic regulatory properties. The aim of this systematic review was to synthesize available evidence regarding the metabolic and pancreatic effects of resveratrol in diabetes mellitus. A systematic literature search of the PubMed/MEDLINE database (2011–2025) identified preclinical studies, randomized controlled trials, systematic reviews, and meta-analyses investigating resveratrol in diabetic contexts. Evidence from experimental and clinical studies indicates that resveratrol may improve glycemic control, attenuate inflammatory responses, reduce oxidative stress, and protect pancreatic β-cell function, primarily through activation of signaling pathways such as sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK). Most available evidence originates from studies in type 2 diabetes mellitus or experimental models of diabetes. Nevertheless, several mechanisms identified in these studies–including modulation of oxidative stress, inflammation, and pancreatic tissue remodeling–may also be relevant to diseases characterized by combined exocrine and endocrine pancreatic dysfunction. In this context, resveratrol may influence biological processes related to the exocrine–endocrine pancreatic axis, including pancreatic inflammation, fibrosis, and β-cell preservation. Overall, current evidence supports the metabolic and pancreatic protective effects of resveratrol in diabetes. However, direct studies investigating its role in pancreatogenic diabetes remain scarce. Future research specifically targeting pancreatic diseases associated with diabetes is needed to clarify the therapeutic potential of resveratrol in disorders affecting the exocrine–endocrine pancreatic axis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.